
A. 300-19 cells



B. 300-19 cells transfected with FOLR1




FIG. 1



Cell Line
ABC
Score
KB
>1,700,0000
3 homo
IGROV1
260,000
3 homo
JEG3
41,000
2/3 hetero
OVCAR3
4,000
1~2 hetero

FIG. 2



Ovarian Tumors
NSCLC Tumors
2 hetero
2-3 homo
3 homo
~41,000 ABC
~41,000-260,000 ABC
≥ 260,000 ABC
50.0 µm
200.0 µm
50.0 µm

FIG. 3



Ovarian Carcinomas
Non Small Cell Lung Carcinomas
Legend
Homo
Hetero
Homo/ Hetero
Negative
ABC value
≥ 260,000
41,000-260,000
4,000-41,000
< 4,000
31/57 54%
11/14 79%
16/23 70%
2/6 33%
1/2 50%
24/41 59%
7/7 100 %
6/9 67%
8/17 47%
3/8 38%
1/24 4%
1/24 4%
Intensity Score
Subtype
Serous
Endometrioid
Mucinous
Transitional cell
Papillary adenocarcinoma
Adenocarcinoma
Large cell undifferentiated carcinoma
Squamous cell carcinoma

FIG. 4




FIG. 5




FIG. 6



PBS
B-huMOV19-SPDB-DM4
C-huMOV19-Peg4-Mal-DM4
D-huC242-SPDB-DM4
E-huC242-Peg4-Mal-DM4
Mean tumor volume (mm3)
2000
1500
1000
500
0
0
20
40
60
80
100
120
Days Post Inoculation

FIG. 7



1.2 mg/kg
2.5 mg/kg
5.0 mg/kg
PBS
Median Tumor Volume (mm3)
2000
1500
1000
500
0
0
25
50
75
100
125
150
175
200
Days Post Inoculation

FIG. 8



1.2 mg/kg
2.5 mg/kg
5.0 mg/kg
PBS
Median Tumor Volume (mm3)
1500
1000
500
0
0
20
40
60
80
100
120
Days Post Inoculation

FIG. 9



1.2 mg/kg
2.5 mg/kg
5.0 mg/kg
PBS
Median Tumor Volume (mm3)
2000
1500
1000
500
0
10
20
30
40
50
60
70
80
90
Days Post Inoculation

FIG. 10



PBS
1.2 mg/kg
2.5 mg/kg
5.0 mg/kg
Median Tumor Volume (mm3)
0
100
200
300
400
500
600
20
25
30
35
40
Days Post Inoculation

FIG. 11



1.0 mg/kg
2.5 mg/kg
5 mg/kg
PBS
2000
1500
1000
500
0
0
20
40
60
80
100
120
Median Tumor Volume (mm3)
Days Post Inoculation

FIG. 12



SW620 (40,098 ABC)
1-3 hetero (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H
T47D (97,576 ABC)
1-2 hetero (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H
IGROV-1 (565,481 ABC)
1-3 hetero (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H
300.19/FR1 (830,003 ABC)
3 homo (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H
Hela (1,500,587 ABC)
2-3 hetero (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H
KB (~4,000,000 ABC)
3 homo (1.9 µg/mL)
Flow Cytometry Histogram¹
FL2-H

FIG. 13



2-3 homo (core G03, Pantomics)
2 hetero (core D08, Pantomics)
3 homo (core H13, Pantomics)
2 homo (core A07, Pantomics)

FIG. 14



2-3 homo (P-T-OVA-032610-1)
1-2 hetero (core G14, Pantomics)
3 homo (core A12, Pantomics)
3 focal (core E11, Pantomics)

FIG. 15



2-3 homo (core J05, Pantomics)
2 homo apical (core G10, Pantomics)
3 homo (core F03, Pantomics)
2 hetero (core 29, Tristar)
1-2 Hetero (core H15, Pantomics)

FIG. 16



2 hetero (core G08, Pantomics)
1 hetero (core I11, Pantomics)
3 hetero (core I04, Pantomics)
2 hetero (core G10, Pantomics)

FIG. 17



2 hetero (core G02, Pantomics)
2 homo (core C05, Pantomics)
1 hetero (core E05, Pantomics)

FIG. 18



Namalwa
SW2
Ovcar-3
KB cells
Igrov-1
Skov-3
Jeg-3
% viability
% SF
[IMGN853], M

FIG. 19



Cell lines specifically sensitive to IMGN853 (unconjugated M9346A decreases activity of the conjugate)
Cell lines not sensitive to IMGN853 (unconjugated M9346A does not change activity of the conjugate)
KB
Igrov-1
Jeg-3
Skov-3
Ovcar-3
ABC
10^7
10^6
10^5
10^4
10^3
0.01
0.1
1
10
100
IMGN853 IC_{50}, nM

FIG. 20



IGROV-1: 1-3 Homo (XT056-1b)
SKOV-3: Negative (XT010)
Ovcar 3: 1-3 Hetero (XT012)
OV-90: 1-2 Hetero (XT015)

FIG. 21



A. NSCLC
NCI-H2110: 2-3 Homo (XT097)
LXFA737: 2 Homo (5374)
B. Endometrial carcinoma
Ishikawa: 2 Hetero/3 Focal (XT054)
C. Cervical carcinoma
KB: 3 Homo (XT005)

FIG. 22



Salivary Gland, Intercalated ducts: 1-2 Hetero
Pancreas, Ducts: 3 Homo
Esophagus, 0 (negative)
Lung, Respiratory Epithelium: 2 Homo

FIG. 23



Level 3 Intensity
Ovarian Serous Adenocarcinoma, 3 homo
Lung Adenocarcinoma, 3 homo
Level 2 Intensity
Renal Clear Cell Carcinoma, 2 homo
Ovarian Serous Adenocarcinoma, 1-2 hetero
Level 1 Intensity
Renal Clear Cell Carcinoma, 1 hetero
Renal Clear Cell Carcinoma, 0-1 homo

FIG. 24



Ovarian Serous Cystadenocarcinoma, 2-3 homo
Renal Clear Cell Carcinoma, 2 hetero
Lung Adenocarcinoma, negative staining, 0
Ovarian Serous Cystadenocarcinoma, 1-3 homo
Ovarian Serous Cystadenocarcinoma, 1-2 homo
Renal Clear Cell Carcinoma, 0-1 hetero
Level 3 Intensity
Level 2 Intensity
Level 1 Intensity and FOLR1 Negative

FIG. 25